RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/27409164http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/27409164http://www.w3.org/2000/01/rdf-schema#comment"microRNA-27a (miR-27a) is frequently dysregulated in human carcinoma, including gastric cancer. The B-cell translocation gene 2 (BTG2) has been implicated in gastric carcinogenesis. However, till now, the link between miR-27a and BTG2 in gastric cancer has not been reported. Here, we found that two isoforms of mature miR-27a, miR-27a-5p and miR-27-3p, were both frequently overexpressed in gastric cancer tissues and cell lines, whereas the expression level of miR-27-3p in gastric cancer was significantly higher than that of miR-27a-5p. And overexpression of miR-27a-3p, but not miR-27a-5p, markedly promoted gastric cancer cell proliferation in vitro as well as tumor growth in vivo. Further experiments revealed that BTG2 was a direct and functional target of miR-27a-3p in gastric cancer and miR-27a-3p inhibition obviously up-regulated the expression of BTG2. In turn, overexpression of BTG2 triggered G1/S cell cycle arrest, induced subsequent apoptosis, and inhibited C-myc activation following Ras/MEK/ERK signaling pathway, which involved in the biological effects of miR-27a-3p/BTG2 axis on gastric carcinogenesis and cancer progression. Overall, these results suggested that the miR-27a-3p/BTG2 axis might represent a promising diagnostic biomarker for gastric cancer patients and could be a potential therapeutic target in the management of gastric cancer."xsd:string
http://purl.uniprot.org/citations/27409164http://purl.org/dc/terms/identifier"doi:10.18632/oncotarget.10460"xsd:string
http://purl.uniprot.org/citations/27409164http://purl.uniprot.org/core/author"Liu C."xsd:string
http://purl.uniprot.org/citations/27409164http://purl.uniprot.org/core/author"Lin S."xsd:string
http://purl.uniprot.org/citations/27409164http://purl.uniprot.org/core/author"Liu J."xsd:string
http://purl.uniprot.org/citations/27409164http://purl.uniprot.org/core/author"Liang X."xsd:string
http://purl.uniprot.org/citations/27409164http://purl.uniprot.org/core/author"Zhou L."xsd:string
http://purl.uniprot.org/citations/27409164http://purl.uniprot.org/core/author"Wu H."xsd:string
http://purl.uniprot.org/citations/27409164http://purl.uniprot.org/core/author"Zhang L."xsd:string
http://purl.uniprot.org/citations/27409164http://purl.uniprot.org/core/author"Yang L."xsd:string
http://purl.uniprot.org/citations/27409164http://purl.uniprot.org/core/author"Cai G."xsd:string
http://purl.uniprot.org/citations/27409164http://purl.uniprot.org/core/author"Nagao N."xsd:string
http://purl.uniprot.org/citations/27409164http://purl.uniprot.org/core/date"2016"xsd:gYear
http://purl.uniprot.org/citations/27409164http://purl.uniprot.org/core/name"Oncotarget"xsd:string
http://purl.uniprot.org/citations/27409164http://purl.uniprot.org/core/pages"51943-51954"xsd:string
http://purl.uniprot.org/citations/27409164http://purl.uniprot.org/core/title"MiR-27a-3p functions as an oncogene in gastric cancer by targeting BTG2."xsd:string
http://purl.uniprot.org/citations/27409164http://purl.uniprot.org/core/volume"7"xsd:string
http://purl.uniprot.org/citations/27409164http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/27409164
http://purl.uniprot.org/citations/27409164http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/27409164
http://purl.uniprot.org/uniprot/#_P78543-mappedCitation-27409164http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/27409164
http://purl.uniprot.org/uniprot/P78543http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/27409164